Teduglutide
Teduglutide (brand names Gattex and Revestive) is a glucagon-like peptide-2 analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion.[1] In Europe it is marketed under the brand Revestive by Nycomed. It was approved by the United States under the name Gattex on December 21, 2012.
References
- ^ Jeppesen, PB (2012 May). "Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome". Therapeutic advances in gastroenterology. 5 (3): 159–71. PMID 22570676.
{{cite journal}}: Check date values in:|date=(help)
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |